Lifesci Capital Issues Optimistic Outlook for RVMD Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Equities researchers at Lifesci Capital raised their Q4 2026 EPS estimates for shares of Revolution Medicines in a research note issued to investors on Monday, April 13th. Lifesci Capital analyst C. Zhu now forecasts that the company will earn ($2.08) per share for the quarter, up from their prior forecast of ($2.09). The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share.

RVMD has been the subject of several other research reports. Jefferies Financial Group initiated coverage on shares of Revolution Medicines in a research report on Monday, March 16th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday. Evercore reaffirmed an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday. Finally, UBS Group began coverage on shares of Revolution Medicines in a research note on Friday, February 27th. They issued a “buy” rating for the company. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $78.94.

Revolution Medicines Price Performance

NASDAQ RVMD opened at $149.27 on Thursday. Revolution Medicines has a 52 week low of $34.00 and a 52 week high of $155.70. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. The stock has a market cap of $29.58 billion, a price-to-earnings ratio of -25.26 and a beta of 1.01. The company has a 50-day moving average price of $102.10 and a two-hundred day moving average price of $85.20.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter last year, the company earned ($1.12) EPS.

Insider Buying and Selling at Revolution Medicines

In related news, insider Stephen Michael Kelsey sold 4,302 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $427,962.96. Following the completion of the sale, the insider directly owned 295,398 shares of the company’s stock, valued at $29,386,193.04. This represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Xiaolin Wang sold 2,010 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the completion of the sale, the insider owned 116,063 shares of the company’s stock, valued at approximately $11,545,947.24. This trade represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 64,592 shares of company stock valued at $6,488,732. Corporate insiders own 8.20% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Several hedge funds have recently made changes to their positions in RVMD. Nextech Invest Ltd. lifted its position in shares of Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after acquiring an additional 1,304,347 shares in the last quarter. Millennium Management LLC lifted its position in shares of Revolution Medicines by 681.8% in the 1st quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock valued at $5,529,000 after acquiring an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Revolution Medicines by 14.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock valued at $10,615,000 after acquiring an additional 37,345 shares in the last quarter. Invesco Ltd. lifted its position in shares of Revolution Medicines by 19.3% in the 2nd quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock valued at $8,352,000 after acquiring an additional 36,760 shares in the last quarter. Finally, Jump Financial LLC lifted its position in shares of Revolution Medicines by 87.9% in the 2nd quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock valued at $561,000 after acquiring an additional 7,137 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: M&A interest remains a potential upside: commentators say RVMD still looks like an attractive takeover target after positive daraxonrasib data, which could support a takeover premium or strategic interest. Why Revolution Medicines still looks like a prime takeover target
• Positive Sentiment: Bullish clinical/analyst commentary: some analysts and commentators are calling a “Strong Buy” based on daraxonrasib trial wins and pipeline expansions, supporting the view that clinical progress can drive long-term value. Revolution Medicines: ‘Strong Buy’ On Daraxonrasib Win
• Positive Sentiment: Analyst support: Wedbush reaffirmed an “Outperform” rating, signaling continued institutional bullishness despite near-term noise. Revolution Medicines ‘Outperform’ Rating Reaffirmed at Wedbush
• Neutral Sentiment: Minor estimate tweak: LifeSci Capital marginally adjusted its Q4 2026 EPS estimate (from –$2.09 to –$2.08), which is effectively immaterial to near‑term market moves but reflects continued analyst monitoring of spend and development timelines.
• Negative Sentiment: Large concurrent financing upsized to ~ $2.0B (≈10.56M shares at $142 + $500M 0.50% convertible notes) — proceeds earmarked for R&D/commercialization but the deal increases share count and creates dilution risk; convertible terms include an initial conversion price ~ $198.80 (~40% premium to the equity price). Settlement and underwriter option can further increase float, pressuring the stock. Revolution Medicines Prices $2.0 Billion in Concurrent Upsized Offerings
• Negative Sentiment: Analyst cuts from HC Wainwright: multiple downward revisions to quarterly and FY2026 EPS (notably a larger FY downgrade) signal concern about near-term profitability and raise caution on operating-cost and timeline assumptions.
• Negative Sentiment: Insider selling and mixed institutional flows: filings show substantial insider sales and notable portfolio rebalancing by large institutions, which can add selling pressure and amplify volatility. QuiverQuant: Revolution Medicines Announces Pricing of Offerings

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.